Absci (ABSI) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 4, 2026, to be held virtually, with voting available online, by phone, or mail.

• Key priorities for 2026 include clinical proof-of-concept for ABS-201 in androgenetic alopecia and initiation of a global Phase 2 trial for ABS-201 in endometriosis.

• Company advanced ABS-201 from discovery to clinic in two years at a fraction of typical industry cost, and launched Origin-1 AI platform for antibody design.

• Over $144M in cash runway projected into the first half of 2028, supporting ongoing R&D and partnerships.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class II directors (Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj) for terms expiring in 2029.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Procedures for submitting shareholder proposals and director nominations for future meetings are detailed, with deadlines and requirements specified.

Board of directors and corporate governance

• Board consists of seven members divided into three staggered classes, with a mix of industry, technical, and executive expertise.

• Majority of directors are independent under Nasdaq and SEC rules; CEO is not independent.

• Board committees include audit, compensation, and nominating/governance, each with defined charters and independent membership.

• Board diversity considered but no formal diversity policy; focus on complementary skills and high ethical standards.

• Director resignation policy requires any director receiving more withheld than for votes to tender resignation.